QUAD vs ESLT vs LHX vs SRPT

For growth investors, Elbit Systems Ltd.

(ESLT) is the stronger pick with 23. 9% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). Quad/Graphics, Inc. (QUAD) offers the better valuation at 14. 2x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Quad/Graphics, Inc.

(QUAD) is the cheapest at 14. 2x versus Elbit Systems Ltd. at 64. 5x. On forward P/E, Quad/Graphics, Inc. is actually cheaper at 6. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: L3Harris Technologies, Inc. wins at 2. 48x versus Elbit Systems Ltd. 's 3. 48x.

Over the past 5 years, Elbit Systems Ltd.

(ESLT) delivered a total return of +486. 3%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ESLT returned +737. 2% versus QUAD's -23. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elbit Systems Ltd.

(ESLT) is the lower-risk stock at 0. 35β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 479% more volatile than ESLT relative to the S&P 500. On balance sheet safety, Elbit Systems Ltd. (ESLT) carries a lower debt/equity ratio of 23% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Elbit Systems Ltd.

(ESLT) is pulling ahead at 23. 9% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

L3Harris Technologies, Inc.

(LHX) is the more profitable company, earning 7. 3% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 7. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LHX leads at 10. 0% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, L3Harris Technologies, Inc. (LHX) is the more undervalued stock at a PEG of 2. 48x versus Elbit Systems Ltd. 's 3. 48x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Quad/Graphics, Inc. (QUAD) trades at 6. 3x forward P/E versus 57. 3x for Elbit Systems Ltd. — 51. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SRPT: 18. 4% to $24. 63.

In this comparison, QUAD (3.

8% yield), LHX (1. 6% yield), ESLT (0. 3% yield) pay a dividend. SRPT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, L3Harris Technologies, Inc.

(LHX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 1. 6% yield, +346. 1% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LHX: +346. 1%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QUAD (Industrials) and ESLT (Industrials) and LHX (Industrials) and SRPT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QUAD is a small-cap deep-value stock; ESLT is a mid-cap high-growth stock; LHX is a mid-cap quality compounder stock; SRPT is a small-cap high-growth stock. QUAD, LHX pay a dividend while ESLT, SRPT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.